newsfilter
← Latest News
GlobeNewswire·

Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

PBH
  • Prestige Consumer Healthcare reported Q2 2027 revenue of $336.3 million, a 22.7% increase year-over-year.
  • Q2 2027 diluted EPS was $0.53, while adjusted diluted EPS rose to $1.13 from $1.07 in the prior year.
  • The Breathe Right® portfolio & LaCorium acquisitions contributed $65.1 million to Q2 revenue & $71.0 million to the first six months.
  • First half 2027 revenue totaled $602.0 million, up 15.0% year-over-year, with adjusted diluted EPS reaching $2.11.
  • The company updated its full-year 2027 revenue outlook to $1,280–$1,290 million & adjusted EPS to $4.48–$4.55.
  • The lowered guidance reflects expected revenue reductions due to production variability at the Pillar5 facility affecting Clear Eyes® availability.
  • North American OTC Healthcare segment revenue grew 17.8% in Q2 to $271.8 million, driven by acquisitions & higher sales of CompoundW® & TheraTears®.
  • International OTC Healthcare segment revenue surged 48.7% in Q2 to $64.5 million, fueled by acquisitions & strong Hydralyte® growth.
  • Net cash provided by operating activities for the first six months was $108.7 million, with non-GAAP adjusted free cash flow at $123.0 million.
  • The company's net debt position stood at approximately $2 billion as of September 30, 2026, following the issuance of $400 million in new senior notes.
  • CEO Ron Lombardi expressed confidence in long-term goals including ~10% annual revenue growth & ~8% annual EPS growth over the next three years.
  • The acquisition of Pillar5 aims to provide vertical integration for the eye care supply chain & support future capacity investments.